Vilaprisan in women with uterine fibroids: the randomized phase 2b ASTEROID 1 study
To assess the safety and efficacy of four vilaprisan doses (0.5–4.0 mg) in women with uterine fibroids.
Source: fertstert.org
Vilaprisan in women with uterine fibroids: the randomized phase 2b ASTEROID 1 study
Published in Embryology and Reproductive Medicine
More from Embryology and Reproductive MedicineMore posts in Embryology and Reproductive Medicine »
- Life after Stillbirth
- The possible impact of COVID 19 on fertility and ART
- Human embryonic stem cell–derived blastocyst-like spheroids resemble human trophectoderm during early implantation process
- What support is available for you in hospital if you lose your baby
- Estrogen receptor-α immunoreactivity predicts symptom severity and pain recurrence in deep endometriosis
Be First to Comment